Drug name - Azstarys

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584112 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same Jul, 2032

(9 years from now)

US10584113 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10858341 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10954213 COMMAVE THERAP Compositions comprising methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

US10759778 COMMAVE THERAP Methylphenidate-prodrugs, processes of making and using the same Dec, 2037

(15 years from now)

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5.2MG BASE;EQ 26.1MG BASE CAPSULE;ORAL Prescription
EQ 7.8MG BASE;EQ 39.2MG BASE CAPSULE;ORAL Prescription
EQ 10.4MG BASE;EQ 52.3MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.